The global Alzheimer's drugs market was valued at USD 10.9B in 2025 and is projected to expand at a CAGR of 5.2% from 2026 to 2033. The market is transitioning from volume-driven symptomatic therapies to value-driven disease-modifying therapies (DMTs). Leqembi (lecanemab) and Kisunla (donanemab) a...Read More »
September 2, 2026
The global epilepsy and seizure drugs market was valued at USD 11.3B in 2025 and is projected to reach USD 14.0B by 2033, expanding at a CAGR of 3.0%. The market is shifting from conventional anti-seizure medications (ASMs) to newer therapies with different mechanisms of action. Third-generation A...Read More »
September 2, 2026
A monthly, SKU-level read on the U.S. conditioner category on Amazon - engineered to show where category revenue sits and how to compete for it. 8 tracked KPIs turn raw marketplace signals into decision-grade data for product, pricing, and positioning calls.
...Read More »September 2, 2026
A monthly, SKU-level read on the U.S. eyebrow pencil category on Amazon — engineered to show where category revenue sits and how to compete for it. 8 tracked KPIs turn raw marketplace signals into decision-grade data for product, pricing, and positioning calls.
...Read More »September 2, 2026
A monthly, SKU-level read on the U.S. acne spot treatment category on Amazon - engineered to show where category revenue sits and how to compete for it. 8 tracked KPIs turn raw marketplace signals into decision-grade data for product, pricing, and positioning calls.
...Read More »September 2, 2026
A monthly, SKU-level read on the U.S. compact powder category on Amazon engineered to show where category revenue sits and how to compete for it. 8 tracked KPIs turn raw marketplace signals into decision-grade data for product, pricing, and positioning calls.
...Read More »September 2, 2026
The global Huntington’s disease drugs market was valued at USD 975.1M in 2025 and is projected to grow at a CAGR of 11.4% from 2026 to 2033. Market growth is primarily driven by increasing diagnosis of Huntington's disease, wider adoption of VMAT2 inhibitors, and ongoing efforts to develop d...Read More »
September 2, 2026
The global neurological stroke drugs market was valued at USD 9.5B in 2025 and is expected to expand at a CAGR of 3.6% during the forecast period. The market is driven by increasing adoption of intravenous thrombolytic therapies, direct oral anticoagulants (DOACs), and antiplatelet agents for acut...Read More »
September 2, 2026
The global duchenne muscular dystrophy (DMD) drugs market was valued at USD 1.4B in 2025 and is projected to grow at a CAGR of 5.0% from 2026 to 2033. The market is shifting from corticosteroid-based symptomatic treatment to disease-modifying therapies (DMTs), including exon-skipping drugs and gen...Read More »
September 2, 2026
A monthly, SKU-level read on the U.S. concealer category on Amazon engineered to show where category revenue sits and how to compete for it. 8 tracked KPIs turn raw marketplace signals into decision-grade data for product, pricing, and positioning calls.
...Read More »September 2, 2026
A monthly, SKU-level read on the U.S. eyebrow gel category on Amazon engineered to show where category revenue sits and how to compete for it. 8 tracked KPIs turn raw marketplace signals into decision-grade data for product, pricing, and positioning calls.
...Read More »September 1, 2026
The global amyotrophic lateral sclerosis (ALS) drugs market was valued at USD 900.0M in 2025 and is projected to expand at a CAGR of 7.6% from 2026 to 2033. ALS remains one of the most underserved markets in neurology, characterized by high unmet clinical need, rapid disease progression, and limit...Read More »
September 1, 2026
A monthly, SKU-level read on the U.S. bone supplements category on Amazon - engineered to show where category revenue sits and how to compete for it. 8 tracked KPIs turn raw marketplace signals into decision-grade data for product, pricing and positioning calls.
...Read More »September 1, 2026
The global migraine drugs market was valued at USD 8.3B in 2025 and is projected to reach USD 16.0B by 2033, expanding at a CAGR of 8.5%. The market is transitioning from conventional acute therapies, including triptans and nonsteroidal anti-inflammatory drugs (NSAIDs), toward targeted CGRP monocl...Read More »
September 1, 2026
A monthly, SKU-level read on the U.S. beard oil category on Amazon - engineered to show where category revenue sits and how to compete for it. 8 tracked KPIs turn raw marketplace signals into decision-grade data for product, pricing, and positioning calls.
...Read More »September 1, 2026
A monthly, SKU-level read on the U.S. bronzer category on Amazon - engineered to show where category revenue sits and how to compete for it. 8 tracked KPIs turn raw marketplace signals into decision-grade data for product, pricing, and positioning calls.
...Read More »September 1, 2026
A monthly, SKU-level read on the U.S. beard trimmer category on Amazon - engineered to show where category revenue sits and how to compete for it. 8 tracked KPIs turn raw marketplace signals into decision-grade data for product, pricing, and positioning calls.
...Read More »August 31, 2026
A monthly, SKU-level read on the U.S. beard wash category on Amazon - engineered to show where category revenue sits and how to compete for it. 8 tracked KPIs turn raw marketplace signals into decision-grade data for product, pricing, and positioning calls.
...Read More »August 31, 2026
A monthly, SKU-level read on the U.S. beard balm category on Amazon - engineered to show where category revenue sits and how to compete for it. 8 tracked KPIs turn raw marketplace signals into decision-grade data for product, pricing, and positioning calls.
...Read More »August 31, 2026
The global myasthenia gravis drugs market was valued at USD 7.1B in 2025 and is projected to reach USD 10.9B by 2033, expanding at a CAGR of 4.6%. For years, treatment relied mainly on pyridostigmine and corticosteroids, drugs that ease symptoms but don't address the root cause of the disease. Tha...Read More »
August 31, 2026
Tell us what you need. We reply within one working day.
This report has a service guarantee. We stand by our report quality.
Your transaction & personal information is safe and secure.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.